Therapy Detail

Therapy Name Mirvetuximab Soravtansine
Synonym
Therapy Description

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Drug Name Trade Name Synonyms Drug Classes Drug Description
Mirvetuximab Soravtansine IMGN853|M9346A-sulfo-SPDB-DM4 FOLR1-targeted Therapy 12 Mirvetuximab Soravtansine (IMGN853) is an antibody-drug conjugate comprised of an antibody directed against Folr1 linked to the tubulin polymerization-inhibiting drug DM4, leading to cell death in Folr1-expressing tumors (PMID: 26136852, PMID: 25904506).
Molecular Profile Indication/Tumor Type Response Type Therapy Name Approval Status Evidence Type Efficacy Evidence References
Unknown unknown Advanced Solid Tumor not applicable Mirvetuximab Soravtansine Phase I Actionable In a Phase I trial, Mirvetuximab Soravtansine (IMGN853) demonstrated safety and preliminary efficacy in patients with advanced solid tumors, with a clinical benefit rate of 23% (12/43), including partial response in 2 patients, both with epithelial ovarian cancer, CA125 response in 5 patients, and stable disease for greater than 4 months in 5 patients (PMID: 28440955). 28440955
Clinical Trial Phase Therapies Title Recruitment Status
NCT02606305 Phase I Bevacizumab Carboplatin Doxorubicin Mirvetuximab Soravtansine Study of IMGN853 in Comb. With Bevacizumab, Carboplatin or PLD in Adults With FRa + Adv. EOC, Primary Peritoneal, Fallopian Tube, or Endometrial Cancer Recruiting
NCT02631876 Phase II Paclitaxel + Pegylated liposomal-doxorubicin Gemcitabine Topotecan Mirvetuximab Soravtansine PH2 Study of IMGN853 vs Investigator's Choice of Chemo in Adults With FRa+ Adv. EOC, Primary Peritoneal or Primary Fallopian Tube Cancer Active, not recruiting
NCT02996825 Phase I Mirvetuximab Soravtansine Mirvetuximab Soravtansine and Gemcitabine Hydrochloride in Treating Patients With FRa-Positive Recurrent Ovarian, Primary Peritoneal, Fallopian Tube, Endometrial, or Triple Negative Breast Cancer Recruiting
NCT03106077 Phase II Mirvetuximab Soravtansine Mirvetuximab Soravtansine in Localized Triple-Negative Breast Cancer (TNBC) Recruiting
NCT01609556 Phase I Mirvetuximab Soravtansine First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of IMGN853 in Adults With Ovarian Cancer and Other FOLR1-Positive Solid Tumors Active, not recruiting
NCT03832361 Phase II Mirvetuximab Soravtansine Evaluation of Mirvetuximab Soravtansine (IMGN853) in Women With Folate Receptor-alpha Positive Endometrial Cancer Not yet recruiting